Latest news with #DavidCrane
Yahoo
5 days ago
- Health
- Yahoo
Charity ready for clinical trials of cancer drug
A Shropshire charity says it is ready to start clinical trials on a new drug to treat lung cancer. Although the charity Brightwater Research was formed in 2019, its founders have spent 15 years developing the drug Valoxydin, and said the results of initial testing had been positive. Operations manager David Crane said the drug was designed to prevent tumours spreading around the body. The charity is currently seeking funding to fully develop the drug so it can eventually be used to treat patients. Decisions about which medicines are made available on the NHS are made by different organisations in England, Wales and Scotland. Decisions are usuaully based on factors, including the evidence available about a drug and the length by which it could extend patients' lives. Input from experts and public involvement is also considered. Mr Crane said Valoxydin was an anti-metastatic drug which targeted the formation of secondary tumours – also known as metastases - in the body and stopped the primary cancer from spreading. Testing showed the drug could potentially reduce the spread of lung cancer by approximately 80% in animal models, he added. Fellow trustee Ted Youngman, whose father died with lung and brain cancer 15 years ago, said from the initial theory about how the treatment might work, they had begun to experiment with the drug in a petri dish and had gone through more than 50 variations to reach the point it was now at. 'Tremendous' "There's a lot of work still to go, but this is tremendous," Mr Youngman said. He added: "It's much easier to stop [cancer] from spreading than it is to treat it once it's already spread. "That's the approach we're taking, which we think is a bit different from other treatments before now." The charity's founders believe it might be possible the drug could be developed for use in the treatment of liver, kidney and bowel cancer, but added a significant amount of additional funding would be needed for further research. Conversations with potential large-scale backers had already begun, Mr Crane said. He said the process could take two to three years, at which point it might be ready for consideration by the NHS. The drug would be taken as a pill, which would mean it was relatively easy to administer to patients. Mr Crane said the drug would need to be taken daily for the rest of the patient's life – or until another solution is discovered. Follow BBC Shropshire on BBC Sounds, Facebook, X and Instagram. More on this story Breast screening trial hopes to find cancers earlier Cyclist challenging 'stage four cancer perceptions' Penile cancer medical trial 'gave me two more years' Related internet links Brightwater Research Solve the daily Crossword
BBC News
5 days ago
- Health
- BBC News
Shrewsbury cancer charity ready for clinical trials of new drug
A Shropshire charity says it is ready to start clinical trials on a new drug to treat lung the charity Brightwater Research was formed in 2019, its founders have spent 15 years developing the drug Valoxydin, and said the results of initial testing had been manager David Crane said the drug was designed to prevent tumours spreading around the charity is currently seeking funding to fully develop the drug so it can eventually be used to treat patients. Decisions about which medicines are made available on the NHS are made by different organisations in England, Wales and are usuaully based on factors, including the evidence available about a drug and the length by which it could extend patients' from experts and public involvement is also considered. Mr Crane said Valoxydin was an anti-metastatic drug which targeted the formation of secondary tumours – also known as metastases - in the body and stopped the primary cancer from showed the drug could potentially reduce the spread of lung cancer by approximately 80% in animal models, he trustee Ted Youngman, whose father died with lung and brain cancer 15 years ago, said from the initial theory about how the treatment might work, they had begun to experiment with the drug in a petri dish and had gone through more than 50 variations to reach the point it was now at. 'Tremendous' "There's a lot of work still to go, but this is tremendous," Mr Youngman added: "It's much easier to stop [cancer] from spreading than it is to treat it once it's already spread."That's the approach we're taking, which we think is a bit different from other treatments before now."The charity's founders believe it might be possible the drug could be developed for use in the treatment of liver, kidney and bowel cancer, but added a significant amount of additional funding would be needed for further with potential large-scale backers had already begun, Mr Crane said the process could take two to three years, at which point it might be ready for consideration by the drug would be taken as a pill, which would mean it was relatively easy to administer to Crane said the drug would need to be taken daily for the rest of the patient's life – or until another solution is discovered. Follow BBC Shropshire on BBC Sounds, Facebook, X and Instagram.
Yahoo
28-04-2025
- Automotive
- Yahoo
Vertu Motors partners with Solera cap hpi to boost digital integration
UK motor retailer Vertu Motors has partnered with Solera cap hpi to advance its digital integration across its dealership network. Under the agreement, Solera cap hpi will supply its HPI Check provenance data to Vertu Motors through a shared risk commercial model. This arrangement enables Vertu to access all necessary data points to support vehicle retail operations, with the flexible structure intended to improve operational efficiency and advance the group's omnichannel retail strategy that combines physical showrooms with digital platforms. Solera cap hpi will also provide current and forecast vehicle valuations, which will help Vertu Motors refine its smart pricing strategies and inform decision-making processes across its network of over 200 dealerships. Vertu represents more than 30 major manufacturers. Vertu Motors chief operations officer David Crane said: 'The new agreement builds on our long-standing relationship with Solera cap hpi. 'It supports the company's commitment to data-led decision-making in a fast-paced market, with the ability to update vehicle pricing from a central source, bringing even more efficiencies into the group. 'We use data-driven decision-making across our organisation to generate enhanced returns and deliver a better customer experience. Data drives our omnichannel development, bringing 'bricks and clicks' together.' The latest move follows Vertu's recent £3.6m ($4.79) investment to expand its presence in the South West, including the launch of two new Volvo dealerships in Yeovil and Plymouth. Solera cap hpi strategic retail head Wendy Swaine said: 'New investment in our data will see the HPI Check continue to lead the industry and provide our retailers and wider customers with the information they need to accurately buy and sell vehicles.' Solera cap hpi is a provider of real-time vehicle valuations and provenance data to UK dealerships. Last year, the company delivered more than 143.8 million valuations and completed 29.2 million HPI Checks through its digital platforms. "Vertu Motors partners with Solera cap hpi to boost digital integration" was originally created and published by Motor Finance Online, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
28-04-2025
- Automotive
- Yahoo
Vertu Motors partners with Solera cap hpi to boost digital integration
UK motor retailer Vertu Motors has partnered with Solera cap hpi to advance its digital integration across its dealership network. Under the agreement, Solera cap hpi will supply its HPI Check provenance data to Vertu Motors through a shared risk commercial model. This arrangement enables Vertu to access all necessary data points to support vehicle retail operations, with the flexible structure intended to improve operational efficiency and advance the group's omnichannel retail strategy that combines physical showrooms with digital platforms. Solera cap hpi will also provide current and forecast vehicle valuations, which will help Vertu Motors refine its smart pricing strategies and inform decision-making processes across its network of over 200 dealerships. Vertu represents more than 30 major manufacturers. Vertu Motors chief operations officer David Crane said: 'The new agreement builds on our long-standing relationship with Solera cap hpi. 'It supports the company's commitment to data-led decision-making in a fast-paced market, with the ability to update vehicle pricing from a central source, bringing even more efficiencies into the group. 'We use data-driven decision-making across our organisation to generate enhanced returns and deliver a better customer experience. Data drives our omnichannel development, bringing 'bricks and clicks' together.' The latest move follows Vertu's recent £3.6m ($4.79) investment to expand its presence in the South West, including the launch of two new Volvo dealerships in Yeovil and Plymouth. Solera cap hpi strategic retail head Wendy Swaine said: 'New investment in our data will see the HPI Check continue to lead the industry and provide our retailers and wider customers with the information they need to accurately buy and sell vehicles.' Solera cap hpi is a provider of real-time vehicle valuations and provenance data to UK dealerships. Last year, the company delivered more than 143.8 million valuations and completed 29.2 million HPI Checks through its digital platforms. "Vertu Motors partners with Solera cap hpi to boost digital integration" was originally created and published by Motor Finance Online, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
